Addiction is a brain disorder characterized by compulsive engagement in rewarding stimuli despite adverse consequences. A number of psychosocial factors are involved, but it is a biological process—one that is induced by repeated exposure to an addictive stimulus—that is the core pathology that drives the development and maintenance of an addiction. Addictive stimuli are reinforcing and intrinsically rewarding.
Classic hallmarks of addiction include impaired control over substances or behavior, preoccupation with substance or behavior, and continued use despite consequences. Habits and patterns associated with addiction are typically characterized by immediate gratification (short-term reward), coupled with delayed deleterious effects (long-term costs). Addiction has a massive overall economic cost to society, and, more importantly, is destructive to individuals, their families, and the social well-being of society as a whole.
The American Society of Addiction Medicine defines addiction as follows:
Addiction is a treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the environment, and an individual’s life experiences. People with addiction use substances or engage in behaviors that become compulsive and often continue despite harmful consequences.
Addiction is a brain disorder characterized by compulsive engagement in rewarding stimuli despite adverse consequences. The two properties that characterize all addictive stimuli are that they are reinforcing (in other words, they increase the likelihood that a person will seek repeated exposure to them) and intrinsically rewarding (meaning they are perceived as being inherently positive, desirable, and pleasurable).
Classic hallmarks of addiction include impaired control over substances or behavior, preoccupation with substance or behavior, and continued use despite consequences. Habits and patterns associated with addiction are typically characterized by immediate gratification (short-term reward), coupled with delayed deleterious effects (long-term costs).
Types of addiction
|Addiction and dependence glossary|
|* addiction – a biopsychosocial disorder characterized by compulsively seeking to achieve a desired effect, such as intoxication, despite harm and adverse consequences to self and others
Addiction has traditionally been used in reference to substance abuse where there are obvious physical dependencies. However, the term has been expanded to include behaviors that may lead to a reward (such as gambling, eating, sexual activity, or even shopping). A gene transcription factor known as ΔFosB has been identified as a necessary common factor involved in both behavioral and drug addictions, which are associated with the same set of neural adaptations in the reward system.
Examples of drug and behavioral addictions include alcoholism, marijuana addiction, amphetamine addiction, cocaine addiction, nicotine addiction, opioid addiction, food addiction, video game addiction, gambling addiction, and sexual addiction. The only behavioral addiction recognized by the DSM-5 and the ICD-10 is gambling addiction. With the introduction of the ICD-11 gaming addiction was appended.
The term addiction is misused frequently to refer to other compulsive behaviors or disorders, particularly dependence. Substance dependence is an adaptive state that develops from repeated drug administration, and which results in withdrawal (a set of unpleasant physical symptoms that are opposite of the effects of the drug) upon cessation of use. Addiction is compulsive, out-of-control use of a substance or performance of a behavior despite negative consequences. Addiction can occur in the absence of dependence, and dependence can occur in the absence of addiction, although the two often occur together.
ΔFosB, a gene transcription factor, has been identified as playing a critical role in the development of addictive states in both behavioral addictions and drug addictions. Overexpression of ΔFosB in the nucleus accumbens is necessary and sufficient for many of the neural adaptations seen in drug addiction; it has been implicated in addictions to alcohol, cannabinoids, cocaine, nicotine, phenylcyclidine, and substituted amphetamines as well as addictions to natural rewards such as sex, exercise, and food.
In the nucleus accumbens, ΔFosB functions as a "sustained molecular switch" and "master control protein" in the development of an addiction. In other words, once "turned on" (sufficiently overexpressed) ΔFosB triggers a series of transcription events that ultimately produce an addictive state (compulsive reward-seeking involving a particular stimulus); this state is sustained for months after cessation of drug use due to the abnormal and exceptionally long half-life of ΔFosB isoforms. ΔFosB expression in D1-type nucleus accumbens medium spiny neurons directly and positively regulates drug self-administration and reward sensitization through positive reinforcement while decreasing sensitivity to aversion.
Besides increased ΔFosB expression in the nucleus accumbens, there are many other correlations in the neurobiology of behavioral addictions with drug addictions.
Behaviors like gambling have been linked to the brain's capacity to anticipate rewards. The reward system can be triggered by early detectors of the behavior, and trigger dopamine neurons to begin stimulating behaviors. But in some cases, it can lead to many issues due to error, or reward-prediction errors. These errors can act as teaching signals to create a complex behavior task over time.
One of the most important discoveries of addictions has been the drug based reinforcement and, even more important, reward based learning processes. Several structures of the brain are important in the conditioning process of behavioral addiction; these subcortical structures form the brain regions known as the reward system. One of the major areas of study is the amygdala, a brain structure which involves emotional significance and associated learning. Research shows that dopaminergic projections from the ventral tegmental area facilitate a motivational or learned association to a specific behavior. Dopamine neurons take a role in the learning and sustaining of many acquired behaviors. The most common mechanism of dopamine is to create addictive properties along with certain behaviors.
There are three stages to the dopamine reward system: bursts of dopamine, triggering of behavior, and further impact to the behavior. Once electronically signaled, possibly through the behavior, dopamine neurons let out a ‘burst-fire’ of elements to stimulate areas along fast transmitting pathways. The behavior response then perpetuates the striated neurons to further send stimuli. Once the behavior is triggered, it is difficult to work away from the dopamine reward system.
Substance use disorder
Substance use disorder (SUD), also known as a drug use disorder, is the persistent use of drugs (including alcohol) despite substantial harm and adverse consequences. Such addiction can be defined as "the compulsive seeking and taking of drugs despite horrendous consequences or loss of control over drug use." Substance use disorders are characterized by an array of mental, physical, and behavioral symptoms that may cause problems related to loss of control, strain to one's interpersonal life, hazardous use, tolerance, and withdrawal.
In the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), substance abuse and substance dependence were merged into the category of substance use disorders.ref name=DSM-5/> The severity of substance use disorders can vary widely; in the diagnosis of a SUD, the severity of an individual's SUD is qualified as mild, moderate, or severe on the basis of how many of the 11 diagnostic criteria are met.
Drug classes that are involved in SUD include: alcohol; caffeine; cannabis; hallucinogens (such as arylcyclohexylamines); other hallucinogens (such as LSD); inhalants; opioids; sedatives, hypnotics, or anxiolytics; stimulants; tobacco; and other or unknown substances.
Addiction exacts an "astoundingly high financial and human toll" on individuals and society as a whole. In the United States, the total economic cost to society is greater than that of all types of diabetes and all cancers combined:
Risky substance use and untreated addiction account for one-third of inpatient hospital costs and 20 percent of all deaths in the United States each year, and cause or contribute to more than 100 other conditions requiring medical care, as well as vehicular crashes, other fatal and non-fatal injuries, overdose deaths, suicides, homicides, domestic discord, the highest incarceration rate in the world and many other costly social consequences. The economic cost to society is greater than the cost of diabetes and all cancers combined.
These costs arise from the direct adverse effects of drugs and associated healthcare costs, long-term complications (such as lung cancer from smoking tobacco products, liver cirrhosis and dementia from chronic alcohol consumption, and meth mouth from methamphetamine use), the loss of productivity and associated welfare costs, fatal and non-fatal accidents, suicides, homicides, and incarceration, among others.
Diagnosis of substance use disorder (SUD) usually involves an in-depth examination, typically by psychiatrist, psychologist, or drug and alcohol counselor. The most commonly used guidelines are published in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
The 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) uses the term "substance use disorder" to refer to a spectrum of drug use-related disorders. The DSM-5 eliminates the terms "abuse" and "dependence" from diagnostic categories, instead using the specifiers of mild, moderate and severe to indicate the extent of disordered use. These specifiers are determined by the number of diagnostic criteria present in a given case. In the DSM-5, the term drug addiction is synonymous with severe substance use disorder.
There are 11 diagnostic criteria which can be broadly categorized into issues arising from substance use related to loss of control, strain to one's interpersonal life, hazardous use, and pharmacologic effects. DSM-5 guidelines for the diagnosis of a substance use disorder requires that the individual have significant impairment or distress from their pattern of drug use, and at least two of the symptoms listed below in a given year.
- Using more of a substance than planned, or using a substance for a longer interval than desired
- Inability to cut down despite desire to do so
- Spending substantial amount of the day obtaining, using, or recovering from substance use
- Cravings or intense urges to use
- Repeated usage causes or contributes to an inability to meet important social, or professional obligations
- Persistent usage despite user's knowledge that it is causing frequent problems at work, school, or home
- Giving up or cutting back on important social, professional, or leisure activities because of use
- Using in physically hazardous situations, or usage causing physical or mental harm
- Persistent use despite the user's awareness that the substance is causing or at least worsening a physical or mental problem
- Tolerance: needing to use increasing amounts of a substance to obtain its desired effects
- Withdrawal: characteristic group of physical effects or symptoms that emerge as amount of substance in the body decreases
Tolerance is the process by which the body continually adapts to the substance and requires increasingly larger amounts to achieve the original effects. Physical dependence occurs when the body has adjusted by incorporating the substance into its "normal" functioning – attained homeostasis – and therefore physical withdrawal symptoms occur upon cessation of use. Symptoms of withdrawal generally include, but are not limited to, body aches, anxiety, irritability, intense cravings for the substance, nausea, hallucinations, headaches, cold sweats, tremors, and seizures.
There are additional qualifiers and exceptions outlined in the DSM. For instance, if an individual is taking opiates as prescribed, they may experience physiologic effects of tolerance and withdrawal, but this would not cause an individual to meet criteria for a SUD without additional symptoms also being present.
Medical researchers who actively study addiction have criticized the DSM classification of addiction for being flawed and involving arbitrary diagnostic criteria. Writing in 2013, Thomas Insel, the director of the United States National Institute of Mental Health discussed the invalidity of the DSM-5's classification of mental disorders:
While DSM has been described as a "Bible" for the field, it is, at best, a dictionary, creating a set of labels and defining each. The strength of each of the editions of DSM has been "reliability" – each edition has ensured that clinicians use the same terms in the same ways. The weakness is its lack of validity. Unlike our definitions of ischemic heart disease, lymphoma, or AIDS, the DSM diagnoses are based on a consensus about clusters of clinical symptoms, not any objective laboratory measure. In the rest of medicine, this would be equivalent to creating diagnostic systems based on the nature of chest pain or the quality of fever.
Given that addiction manifests in structural changes to the brain, it is possible that non-invasive neuroimaging scans obtained via MRI could be used to help diagnose addiction in the future. As a diagnostic biomarker, ΔFosB expression could be used to diagnose addiction, but this would require a brain biopsy and therefore is not used in clinical practice.
Treatment for substance abuse disorder is not simple. Rather than a single treatment, a variety of different approaches are required for success:
In order to be effective, all pharmacological or biologically based treatments for addiction need to be integrated into other established forms of addiction rehabilitation, such as cognitive behavioral therapy, individual and group psychotherapy, behavior-modification strategies, twelve-step programs, and residential treatment facilities.
Depending on the severity of use, and the given substance, early treatment of acute withdrawal may include medical detoxification. Of note, acute withdrawal from heavy alcohol use must be done under medical supervision to prevent a potentially deadly withdrawal syndrome known as delirium tremens.
Therapeutic treatments usually involve planning for specific ways to avoid the addictive stimulus, and therapeutic interventions intended to help a client learn healthier ways to find satisfaction. Therapists attempt to tailor intervention approaches to specific influences that affect addictive behavior, using therapeutic interviews in an effort to discover factors that led a person to embrace unhealthy, addictive sources of pleasure or relief from pain.
A meta-analytic review on the efficacy of various behavioral therapies for treating drug and behavioral addictions found that cognitive behavioral therapy (such as relapse prevention and contingency management), motivational interviewing, and a community reinforcement approach were effective interventions with moderate effect sizes.
Clinical and preclinical evidence indicate that consistent aerobic exercise, especially endurance exercise (such as marathon running), actually prevents the development of certain drug addictions and is an effective adjunct treatment for drug addiction, and for psychostimulant addiction in particular. Consistent aerobic exercise reduces drug addiction risk, decreases drug self-administration, reduces the likelihood of relapse, and induces opposite effects on striatal dopamine receptor D2 (DRD2) signaling (increased DRD2 density) to those induced by addictions to several drug classes (decreased DRD2 density). Consequently, consistent aerobic exercise may lead to better treatment outcomes when used as an adjunct treatment for drug addiction.
Medication-assisted treatment (MAT) refers to the combination of behavioral interventions and medications to treat substance use disorders. Certain medications can be useful in treating severe substance use disorders. In the United States, several medications, such as disulfiram and methadone, are approved to treat alcohol and opioid use disorders. There are no approved medications for cocaine, methamphetamine, or other substance use disorders.
Approved medications can be used as part of broader treatment plans to help a patient function comfortably without illicit opioids or alcohol. Medications can be used in treatment to lessen withdrawal symptoms. Evidence has demonstrated the efficacy of MAT at reducing illicit drug use and overdose deaths, improving retention in treatment, and reducing HIV transmission.
Alcohol, like opioids, can induce a severe state of physical dependence and produce withdrawal symptoms such as delirium tremens. Because of this, treatment for alcohol addiction usually involves a combined approach dealing with dependence and addiction simultaneously. Benzodiazepines have the largest and the best evidence base in the treatment of alcohol withdrawal and are considered the gold standard of alcohol detoxification.
Pharmacological treatments for alcohol addiction include naltrexone (opioid antagonist), disulfiram, acamprosate, and topiramate. Rather than substituting for alcohol, these drugs are intended to affect the desire to drink, either by directly reducing cravings as with acamprosate and topiramate, or by producing unpleasant effects when alcohol is consumed, as with disulfiram. These drugs can be effective if treatment is maintained, but compliance can be an issue as alcoholic patients often forget to take their medication, or discontinue use because of excessive side effects.
Cannabis is a widely used substance, and demand for effective treatment is increasing. However, abstinence rates following behavioral therapies have been modest, and there are no effective pharmacotherapies for the treatment of cannabis addiction.
Medication assisted treatment has been widely used is in the treatment of nicotine addiction. This usually involves nicotine replacement therapy, nicotinic receptor antagonists, or nicotinic receptor partial agonists. Drugs that act on nicotinic receptors and have been used for treating nicotine addiction include antagonists like bupropion and the partial agonist varenicline.
Opioids cause physical dependence, and treatment typically addresses both dependence and addiction.
Physical dependence is treated using replacement drugs such as suboxone or subutex (both containing the active ingredients buprenorphine) and methadone. Although these drugs perpetuate physical dependence, the goal of opiate maintenance is to provide a measure of control over both pain and cravings. Use of replacement drugs increases the addicted individual's ability to function normally and eliminates the negative consequences of obtaining controlled substances illicitly. Once a prescribed dosage is stabilized, treatment enters maintenance or tapering phases.
In the United States, opiate replacement therapy is tightly regulated in methadone clinics and under the DATA 2000 legislation. In some countries, other opioid derivatives are used as substitute drugs for illegal street opiates, with different prescriptions being given depending on the needs of the individual patient.
There is no effective pharmacotherapy for any form of psychostimulant addiction. Many drugs have been tested, but none have shown conclusive efficacy with tolerable side effects in humans. Despite concerted efforts to identify a pharmacotherapy for managing stimulant use disorders, no widely effective medications have been approved, and psychotherapy remains the mainstay of treatment.
There are many known risk factors associated with an increased chance of developing a substance use disorder (SUD). For example, children born to parents with SUDs have roughly a two-fold increased risk in developing an addiction compared to children born to parents without any SUDs. Other common risk factors are being male, being under 25, having other mental health problems, and lack of familial support and supervision. Psychological risk factors include high impulsivity, sensation seeking, neuroticism, and openness to experience in combination with low conscientiousness.
There are a number of genetic and environmental risk factors for developing an addiction, that vary across the population. Even in individuals with a relatively low genetic risk, exposure to sufficiently high doses of an addictive drug for a long period of time can result in an addiction.
It has long been established that genetic factors along with environmental (such as psychosocial) factors are significant contributors to addiction vulnerability. Epidemiological studies estimate that genetic factors account for 40–60 percent of the risk factors for alcoholism. Similar rates of heritability for other types of drug addiction have been indicated by other studies.
Twin studies highlight the significant role genetics play in addiction. Rarely does only one twin have an addiction: In most cases where at least one twin suffered from an addiction, both did, and often to the same substance. Family studies reveal that if one family member has a history of addiction, the chances of a relative or close family developing an addiction to the same substance or a different addiction are much higher than one who has not been introduced to addiction at a young age. Such "cross addiction" occurs because all addictions work in the same part of the brain.
A number of different environmental factors have been implicated as risk factors for addiction, including various psychosocial stressors. However, an individual's exposure to an addictive drug is by far the most significant environmental risk factor for addiction. The National Institute on Drug Abuse (NIDA) cites lack of parental supervision, the prevalence of peer substance use, drug availability, and poverty as risk factors for substance use among children and adolescents.
The earlier someone starts to use drugs, the higher the chance that they will grow to abuse or become dependent on them later on in life. Statistics have shown that those who start to drink alcohol at a younger age, especially prior to 12 years of age, are more likely to become dependent later on.
Adolescence represents a period of unique vulnerability for developing an addiction. In adolescence, the incentive-rewards systems in the brain mature well before the cognitive control center. This consequentially grants the incentive-rewards systems a disproportionate amount of power in the behavioral decision-making process. Therefore, adolescents are increasingly likely to act on their impulses and engage in risky, potentially addicting behavior before considering the consequences. Not only are adolescents more likely to initiate and maintain drug use, but once addicted they are more resistant to treatment and more liable to relapse.
Most individuals are exposed to and use addictive drugs for the first time during their teenage years. In the United States, for example, over 90 percent of those with an addiction began drinking, smoking, or using illicit drugs before the age of 18.
Individuals with comorbid (co-occurring) mental health disorders such as depression, anxiety, attention-deficit/hyperactivity disorder (ADHD), or post-traumatic stress disorder (PTSD) are more likely to develop substance use disorders. The National Bureau of Economic Research reports a "definite connection between mental illness and the use of addictive substances," and "When other factors are held constant, mental illness does increase use of addictive goods — relative to use by the overall population — by 20 percent for alcohol, 27 percent for cocaine, and 86 percent for cigarettes."
Transgenerational epigenetic inheritance is the transmission of epigenetic markers from one generation to the next (parent–child transmission), affecting the traits and behavioral phenotypes of their offspring (for example, behavioral responses to environmental stimuli) without alteration of the primary structure of DNA (the sequence of nucleotides). In addiction, epigenetic mechanisms play a central role in the pathophysiology of the disease. Some of the alterations to the epigenome which arise through chronic exposure to addictive stimuli during an addiction can be transmitted across generations, in turn affecting the behavior of one's children (such as the child's behavioral responses to addictive drugs and natural rewards). However, the components that are responsible for the heritability of characteristics that make an individual more susceptible to drug addiction in humans remain largely unknown.
Behavioral addiction is a form of addiction that involves a compulsion to engage in an inherently rewarding non-substance-related behavior – sometimes called a "natural reward" – despite adverse consequences to the person's physical, mental, social, or financial well-being.
Addiction to both drugs and behavioral rewards may arise from similar dysregulation of the mesolimbic dopamine system. Preclinical evidence has demonstrated that marked increases in the expression of ΔFosB through repetitive and excessive exposure to a natural reward induces the same behavioral effects and neuroplasticity as occurs in a drug addiction.
Psychiatric and medical classifications
Behavioral addictions were introduced as a new diagnostic category in DSM-5, but only gambling addiction is included. Internet gaming addiction is included in the appendix as a condition for further study. Diagnostic models do not currently include the criteria necessary to identify behaviors as addictions in a clinical setting.
In September 2019, the American Society of Addiction Medicine (ASAM) issued a public statement defining all addiction in terms of brain changes:
Addiction is a treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the environment, and an individual’s life experiences. People with addiction use substances or engage in behaviors that become compulsive and often continue despite harmful consequences.
The type of excessive behaviors identified as being addictive include gambling, food, chocolate, sexual intercourse, use of pornography, use of computers, playing video games, use of the internet and other digital media, exercise, and shopping.
Gambling provides a natural reward which is associated with compulsive behavior and for which clinical diagnostic manuals, namely the DSM-5, have identified diagnostic criteria for an addiction. In order for a person's gambling behavior to meet criteria of an addiction, it shows certain characteristics, such as mood modification, compulsivity, and withdrawal. There is evidence from functional neuroimaging that gambling activates the reward system and the mesolimbic pathway in particular. Similarly, shopping and playing video games are associated with compulsive behaviors in humans and have also been shown to activate the mesolimbic pathway and other parts of the reward system. Based upon this evidence, gambling addiction, video game addiction, and shopping addiction are classified accordingly.
Reviews of both clinical research in humans and preclinical studies involving ΔFosB have identified compulsive sexual activity – specifically, any form of sexual intercourse – as an addiction. Moreover, reward cross-sensitization between amphetamine and sexual activity, meaning that exposure to one increases the desire for both, has been shown to occur preclinically and clinically as a dopamine dysregulation syndrome; ΔFosB expression is required for this cross-sensitization effect, which intensifies with the level of ΔFosB expression.
Reviews of preclinical studies indicate that long-term frequent and excessive consumption of high fat or sugar foods can produce an addiction (food addiction).
Excessive and compulsive Internet use has also been studied, revealing it to be a behavioral addiction with serious psychosocial consequences:
The growing number of researches on Internet addiction indicates that Internet addiction is a psychosocial disorder and its characteristics are as follows: tolerance, withdrawal symptoms, affective disorders, and problems in social relations. Internet usage creates psychological, social, school and/or work difficulties in a person's life. Eighteen percent of study participants were considered to be pathological Internet users, whose excessive use of the Internet was causing academic, social, and interpersonal problems. Excessive Internet use may create a heightened level of psychological arousal, resulting in little sleep, failure to eat for long periods, and limited physical activity, possibly leading to the user experiencing physical and mental health problems such as depression, OCD, low family relationships and anxiety.
Another growing area is social media addiction. Researchers found that not only is social media (particularly Facebook) itself potentially addictive, those who use it may also be at greater risk for substance abuse.
Behavioral addiction is a treatable condition. Treatment options include psychotherapy and psychopharmacotherapy (medications) or a combination of both. Cognitive behavioral therapy (CBT) is the most common form of psychotherapy used in treating behavioral addictions; it focuses on identifying patterns that trigger compulsive behavior and making lifestyle changes to promote healthier behaviors. While CBT does not cure behavioral addiction, it does help with coping with the condition in a healthy way.
Currently, there are no medications approved for treatment of behavioral addictions in general, but some medications used for treatment of drug addiction may also be beneficial with specific behavioral addictions. Any unrelated psychiatric disorders should be kept under control, and differentiated from the contributing factors that cause the addiction.
Due to cultural variations, the proportion of individuals who develop a drug or behavioral addiction within a specified time period (the prevalence) varies over time, by country, and across national population demographics (age group, socioeconomic status, and so forth).
The prevalence of alcohol dependence is not as high as is seen in other regions. In Asia, not only socioeconomic factors but also biological factors influence drinking behavior.
Europe and Oceania
Addiction is widespread in the United States. According to a 2017 poll conducted by the Pew Research Center, almost half of US adults know a family member or close friend who has struggled with a drug addiction at some point in their life.
In spite of the massive overall economic cost to society, which is greater than the cost of diabetes and all forms of cancer combined, most doctors in the US lack the training to effectively address a drug addiction. In 2016, it was reported that only about ten percent, or a little over 2 million, receive any form of treatments, and those that do generally do not receive evidence-based care. A major milestone was reached on March 14, 2016, when the American Board of Medical Specialties (ABMS) formally announced recognition of the field of Addiction Medicine as a medical subspecialty:
This landmark event, more than any other, recognizes addiction as a preventable and treatable disease, helping to shed the stigma that has long plagued it. It sends a strong message to the public that American medicine is committed to providing expert care for this disease and services designed to prevent the risky substance use that precedes it.
In 2019, opioid addiction was acknowledged as a national crisis in the United States. American drug companies were found to have flooded the country with prescription pain pills from 2006 through 2012, despite being aware that they were addictive and that they were fueling addiction and overdoses.
The realities of opioid use and abuse in Latin America may be deceptive if observations are limited to epidemiological findings. According to the Inter-American Commission on Drug Abuse Control, consumption of heroin is low in most Latin American countries, although Colombia is the area's largest opium producer. Mexico, because of its border with the United States, has the highest incidence of use.
- What is the definition of addiction? American Society of Addiction Medicine. Retrieved August 31, 2022.
- Eric Nestler, Steven Hyman, and Robert Malenka, Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (McGraw-Hill, 2008, ISBN 978-0071481274).
- Sara B. Taylor, Candace R. Lewis, and M. Foster Olive, The Neurocircuitry of Illicit Psychostimulant Addiction: Acute and Chronic Effects in Humans Subst Abuse Rehabil 8(4) (2013):29-43. Retrieved August 31, 2022.
- G.A. Marlatt, J.S. Baer, D.M. Donovan, and D.R. Kivlahan, Addictive Behaviors: Etiology and Treatment Annual Review of Psychology 39 (1988): 223–252. Retrieved August 31, 2022.
- Constance Holden, 'Behavioral' Addictions: Do They Exist? Science 294(5544) (2001): 980–982. Retrieved August 31, 2022.
- Alfred J. Robison and Eric J. Nestler, Transcriptional and Epigenetic Mechanisms of Addiction Nature Reviews Neuroscience 12(11) (2011):623-637. Retrieved August 31, 2022.
- Kenneth Blum et al., Sex, Drugs, and Rock ‘N’ Roll: Hypothesizing Common Mesolimbic Activation as a Function of Reward Gene Polymorphisms Psychoactive Drugs 44(1) (2012):38–55. Retrieved August 31, 2022.
- Meredith E. Gansner, Gaming Addiction in ICD-11: Issues and Implications Psychiatric Times, September 12, 2019. Retrieved August 31, 2022.
- Substance-Related and Addictive Disorders Mental Health Gateway. Retrieved August 31, 2022.
- Christopher M. Olsen, Natural Rewards, Neuroplasticity, and Non-Drug Addictions Neuropharmacology 61(7) (2011): 1109–1122. Retrieved August 31, 2022.
- Steven E. Hyman, Robert C. Malenka, and Eric J. Nestler, Neural mechanisms of addiction: the role of reward-related learning and memory Annual Review of Neuroscience 29 (2006):565–598. Retrieved August 31, 2022.
- E.J. Nestler, M. Barrot, and D.W. Self, DeltaFosB: A Sustained Molecular Switch for Addiction Proc Natl Acad Sci U S A 98(20) (2001):11042-22046. Retrieved August 31, 2022.
- Eric J. Nestler, Cellular basis of memory for addiction Dialogues Clin Neurosci 15(4) (2013): 431–443. Retrieved August 31, 2022.
- Gaetano Di Chiara and Valentina Bassareo, Reward System and Addiction: What Dopamine Does and Doesn't Do Current Opinion in Pharmacology 7(1) (2007):69–76. Retrieved August 31, 2022.
- Judson A. Brewer and Marc N. Potenza, The neurobiology and genetics of impulse control disorders: Relationships to drug addictions Biochemical Pharmacology 75(1) (2008):63–75. Retrieved August 31, 2022.
- Jean-Antoine Girault and Paul Greengard, The Neurobiology of Dopamine Signaling Archives of Neurology 61(5) (2004):641–644. Retrieved August 31, 2022.
- American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5 (American Psychiatric Publishing, 2013, ISBN 978-0890425558).
- Substance Abuse and Mental Health Services Administration, Substance Use Disorders Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health, 2016. Retrieved August 31, 2022.
- Dennis Tartaglia, ABMS Officially Recognizes Addiction Medicine as a Subspecialty American Board of Addiction Medicine, March 14, 2016. Retrieved August 31, 2022.
- United Nations Office on Drugs and Crime, International Narcotics Control Board Report: 2013 (United Nations, 2014, ISBN 978-9211482744).
- Drug addiction (substance use disorder) Mayo Clinic. Retrieved August 31, 2022.
- John Horgan, Psychiatry in Crisis! Mental Health Director Rejects Psychiatric "Bible" and Replaces With Nothing Scientific American, May 4, 2013. Retrieved August 31, 2022.
- William H. Hampton, Italia M. Hanik, and Ingrid R. Olson, Substance Abuse and White Matter: Findings, Limitations, and Future of Diffusion Tensor Imaging Research Drug and Alcohol Dependence 197(4) (2019):288–298. Retrieved August 31, 2022.
- M. Walter, et al., Psychosocial Treatment of Addictive Disorders – An Overview of Psychotherapeutic Options and their Efficacy Fortschr Neurol Psychiatr 83(4) (2015):201–210. Retrieved August 31, 2022.
- Wendy J Lynch, Alexis B Peterson, Victoria Sanchez, Jean Abel, and Mark A. Smith, Exercise as a Novel Treatment for Drug Addiction: A Neurobiological and Stage-Dependent Hypothesis Neurosci Biobehav Rev 37(8) (2013):1622–1644. Retrieved August 31, 2022.
- American Psychiatric Association, Practice Guidelines for the Treatment of Psychiatric Disorders (American Psychiatric Publishing, 2006, ISBN 978-0890423851).
- Antoine B. Douaihy, Thomas M. Kelly, and Carl Sullivan, Medications for Substance Use Disorders Soc Work Public Health 28(0) (2013): 264–278. Retrieved August 31, 2022.
- Office of the Surgeon General, Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health (CreateSpace, 2017, ISBN 978-1974580620).
- Ankur Sachdeva, Mona Choudhary, and Mina Chandra, Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond Journal of Clinical and Diagnostic Research 9(9) (2015):VE01–VE07. Retrieved August 31, 2022.
- Bradford T. Winslow, Mary Onysko, and Melanie Hebert, Medications for Alcohol Use Disorder American Family Physician 93(6) (2016):457-465. Retrieved August 31, 2022.
- Mehmet Sofuoglu, Dawn E. Sugarman, and Kathleen M. Carroll, Cognitive Function as an Emerging Treatment Target for Marijuana Addiction Exp Clin Psychopharmacol. 18(2) (2010): 109–119. Retrieved August 31, 2022.
- Peter A. Crooks, Michael T. Bardo, and Linda P. Dwoskin, Nicotinic Receptor Antagonists as Treatments for Nicotine Abuse Adv Pharmacol 69 (2014):513-551. Retrieved August 31, 2022.
- M. Connock et al., Methadone and Buprenorphine for the Management of Opioid Dependence: A Systematic Review and Economic Evaluation Health Technol Assess 11(9) (2007):1-171. Retrieved August 31, 2022.
- Fred F. Ferri, Ferri's Clinical Advisor 2020 (Elsevier, 2019, ISBN 978-0323672542).
- Elaine Fehrman, Vincent Egan, Alexander N. Gorban, Jeremy Levesley, Evgeny M. Mirkes, and Awaz K. Muhammad, Personality Traits and Drug Consumption: A Story Told by Data (Springer, 2019, ISBN 978-3030104412).
- R.D. Mayfield, R.A. Harris, and M.A. Schuckit, Genetic factors influencing alcohol dependence Br J Pharmacol 154(2) (2008): 275–287. Retrieved August 31, 2022.
- Steven M. Melemis, The Genetics of Drug and Alcohol Addiction Addictions and Recovery. Retrieved August 31, 2022.
- What are risk factors and protective factors? National Institute on Drug Abuse, October 2011.
- Age and Substance Abuse Alcohol Rehab. Retrieved August 31, 2022.
- Christopher J. Hammond, Linda C. Mayes, and Marc N. Potenza, Neurobiology of Adolescent Substance Use and Addictive Behaviors: Prevention and Treatment Implications Adolesc Med State Art Rev 25(1) (2014): 15–32. Retrieved August 31, 2022.
- Statistics on Addiction in America Addiction Center. Retrieved August 31, 2022.
- Drug addiction (substance use disorder): Risk factors Mayo Clinic. Retrieved August 31, 2022.
- Marie Bussing-Birks, Mental Illness and Substance Abuse National Bureau of Economic Research. Retrieved August 31, 2022.
- F.M. Vassoler and G. Sadri-Vakili, Mechanisms of transgenerational inheritance of addictive-like behaviors Neuroscience 264 (2014): 198–206. Retrieved August 31, 2022.
- Dan J. Stein, Eric Hollander, and Barbara O. Rothbaum (eds.), Textbook of Anxiety Disorders (American Psychiatric Publishing, Inc., 2009, ISBN 1585622540).
- Jon E. Grant, Marc N. Potenza, Aviv Weinstein, and David A. Gorelick, Introduction to Behavioral Addictions Am J Drug Alcohol Abuse 36(5) (2010):233-241. Retrieved August 31, 2022.
- Seyyed Salman Alavi, Mohammad Reza Maracy, Fereshte Jannatifard, and Mehdi Eslami, The effect of psychiatric symptoms on the internet addiction disorder in Isfahan's University students J Res Med Sci. 16(6) (2011):793–800. Retrieved August 31, 2022.
- Fuchun Lin, Yan Zhou, Yasong Du, Lindi Qin, Zhimin Zhao, Jianrong Xu, and Hao Lei, Abnormal White Matter Integrity in Adolescents with Internet Addiction Disorder: A Tract-Based Spatial Statistics Study PLoS One 7(1) (2012). Retrieved August 31, 2022.
- Sang Hee Kim, Sang-Hyun Baik, Chang Soo Park, Su Jin Kim, Sung Won Choi, and Sang Eun Kim, Reduced Striatal Dopamine D2 Receptors in People With Internet Addiction Neuroreport 22(8) (2011):407-411. Retrieved August 31, 2022.
- Craving Facebook? UAlbany Study Finds Social Media to be Potentially Addictive, Associated with Substance Abuse News Center, University at Albany, State University of New York, December 9, 2014. Retrieved August 31, 2022.
- Jon Grant, Impulse Control Disorders: A Clinician's Guide to Understanding and Treating Behavioral Addictions (W. W. Norton & Company, 2008, ISBN 978-0393705218).
- Chiao-Chicy Chen and Shih-Jiun Yin, Alcohol abuse and related factors in Asia Int. Rev. Psychiatry 20(5) (2008):425-433. Retrieved August 31, 2022.
- Amy Peacock et al., Global statistics on alcohol, tobacco and illicit drug use: 2017 status report Addiction 113(10) (2018):1905-1926. Retrieved August 31, 2022.
- John Gramlich, Nearly half of Americans have a family member or close friend who's been addicted to drugs Pew Research Center, October 26, 2017. Retrieved August 31, 2022.
- Nora Volkow, A Major Step Forward for Addiction Medicine National Institute on Drug Abuse, March 31, 2016. Retrieved August 31, 2022.
- Katelyn Newman, Amid Opioid Crisis, Large Drug Companies Pushed 76 Billion Pain Pills Across U.S. US News & World Report, July 17, 2019. Retrieved August 31, 2022.
- Pacurucu Castillo, José Marcelo, Adrián Hernández, and Renato D. Alarcón, World Opioid and Substance Use Epidemic: A Latin American Perspective Psychiatry Online.org, January 24, 2019. Retrieved August 31, 2022.
ReferencesISBN links support NWE through referral fees
- American Psychiatric Association. Practice Guidelines for the Treatment of Psychiatric Disorders. American Psychiatric Publishing, 2006. ISBN 978-0890423851
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. American Psychiatric Publishing, 2013. ISBN 978-0890425558
- Fehrman, Elaine, Vincent Egan, Alexander N. Gorban, Jeremy Levesley, Evgeny M. Mirkes, and Awaz K. Muhammad. Personality Traits and Drug Consumption: A Story Told by Data. Springer, 2019. ISBN 978-3030104412
- Ferri, Fred F. Ferri's Clinical Advisor 2020. Elsevier, 2019. ISBN 978-0323672542
- Grant, Jon. Impulse Control Disorders: A Clinician's Guide to Understanding and Treating Behavioral Addictions. W. W. Norton & Company, 2008. ISBN 978-0393705218
- Nestler, Eric, Steven Hyman, and Robert Malenka. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. McGraw-Hill, 2008. ISBN 978-0071481274
- Office of the Surgeon General. Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. CreateSpace, 2017. ISBN 978-1974580620
- Stein, Dan J., Eric Hollander, and Barbara O. Rothbaum (eds.). Textbook of Anxiety Disorders. American Psychiatric Publishing, Inc., 2009. ISBN 1585622540
- Szalavitz, Maia. Unbroken Brain. Picador, 2017. ISBN 978-1250116444
- United Nations Office on Drugs and Crime. International Narcotics Control Board Report: 2013. United Nations, 2014. ISBN 978-9211482744
All links retrieved June 15, 2023.
- The Science of Addiction: Genetics and the Brain
- Nora Volkow, Why do our brains get addicted? TEDMED.
- Kyoto Encyclopedia of Genes and Genomes (KEGG) signal transduction pathways:
- KEGG – human alcohol addiction
- KEGG – human amphetamine addictionhttps://www.genome.jp/kegg-bin/show_pathway?hsa05030+2354 KEGG – human cocaine addiction]
- Is Your Child a Gaming Addict?
- Addictive Personality Traits: Facts and Fiction
- Outpatient Treatment for Addiction
- How To Help Prevent And Treat Substance Abuse No Matter What Recovery
- Codependency & Addiction Inland Detox
New World Encyclopedia writers and editors rewrote and completed the Wikipedia article in accordance with New World Encyclopedia standards. This article abides by terms of the Creative Commons CC-by-sa 3.0 License (CC-by-sa), which may be used and disseminated with proper attribution. Credit is due under the terms of this license that can reference both the New World Encyclopedia contributors and the selfless volunteer contributors of the Wikimedia Foundation. To cite this article click here for a list of acceptable citing formats.The history of earlier contributions by wikipedians is accessible to researchers here:
The history of this article since it was imported to New World Encyclopedia:
Note: Some restrictions may apply to use of individual images which are separately licensed.